Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single dose of psilocybin help people break free from opioid addiction?

NCT ID NCT06067737

Recruiting now Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests whether a single high dose of psilocybin (the active ingredient in magic mushrooms) can help people with opioid use disorder stay off illicit opioids when added to standard buprenorphine treatment. About 90 adults who have already started buprenorphine will receive either a high dose (30 mg) or a very low dose (1 mg) of psilocybin in a controlled setting. Researchers will track opioid abstinence, treatment retention, and quality of life over 8 weeks to see if psilocybin provides an extra benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a single high dose (30 mg) of psilocybin, compared to a very low dose (1 mg), given alongside standard buprenorphine treatment
What this could lead to
If it works, this could point toward a new way to boost the effectiveness of standard opioid-use-disorder treatment, helping more people stay off illicit opioids and improve their quality of life.
What could go wrong
This is a mid-stage trial with only 90 participants, so results may not apply to everyone. The high dose of psilocybin can cause intense psychological effects, and it is unknown whether any benefit will last beyond the 8-week follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID USE DISORDER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins Center for Psychedelic and Consciousness Research

    RECRUITING

    Baltimore, Maryland, 21224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.